Search research articles
Contact Us
Filters
Showing results (121-130 of 131) with videos related to
Page
of 14
Sort By:
Open Forum Infectious Diseases
|
December 15, 2023
RE: Incidence of SARS-CoV-2 Breakthrough Infections After Vaccination in Adults: A Population-Based Survey Through 1 March 2023
Stacia M DeSantis, Ashraf Yaseen, Tianyao Hao, et al.
The Journal of Infectious Diseases
|
February 2, 2023
Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants
Stacia M DeSantis, Ashraf Yaseen, Tianyao Hao, et al.
The Lancet. Oncology
|
July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
Andrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Pediatrics
|
March 18, 2022
Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents
Sarah E Messiah, Stacia M DeSantis, Luis G Leon-Novelo, et al.
Frontiers in Pediatrics
|
September 4, 2024
Factors associated with elevated SARS-CoV-2 immune response in children and adolescents
Sarah E Messiah, Rhiana Abbas, Emma Bergqvist, et al.
The Journal of Infectious Diseases
|
May 6, 2022
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Michael D Swartz, Stacia M DeSantis, Ashraf Yaseen, et al.
Blood
|
April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
Sherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
Transplantation and Cellular Therapy
|
September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
Andrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
Gastroenterology
|
October 31, 2000
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group
W Fischbach, B Dragosics, M E Kolve-Goebeler, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 131) with videos related to
Sort By:
Page
of 14
Open Forum Infectious Diseases
|
December 15, 2023
RE: Incidence of SARS-CoV-2 Breakthrough Infections After Vaccination in Adults: A Population-Based Survey Through 1 March 2023
Stacia M DeSantis, Ashraf Yaseen, Tianyao Hao, et al.
The Journal of Infectious Diseases
|
February 2, 2023
Incidence and Predictors of Breakthrough and Severe Breakthrough Infections of SARS-CoV-2 After Primary Series Vaccination in Adults: A Population-Based Survey of 22 575 Participants
Stacia M DeSantis, Ashraf Yaseen, Tianyao Hao, et al.
The Lancet. Oncology
|
July 6, 2023
γ-Secretase inhibitor in combination with BCMA chimeric antigen receptor T-cell immunotherapy for individuals with relapsed or refractory multiple myeloma: a phase 1, first-in-human trial
Andrew J Cowan, Margot J Pont, Blythe D Sather, et al.
Pediatrics
|
March 18, 2022
Durability of SARS-CoV-2 Antibodies From Natural Infection in Children and Adolescents
Sarah E Messiah, Stacia M DeSantis, Luis G Leon-Novelo, et al.
Frontiers in Pediatrics
|
September 4, 2024
Factors associated with elevated SARS-CoV-2 immune response in children and adolescents
Sarah E Messiah, Rhiana Abbas, Emma Bergqvist, et al.
The Journal of Infectious Diseases
|
May 6, 2022
Antibody Duration After Infection From SARS-CoV-2 in the Texas Coronavirus Antibody Response Survey
Michael D Swartz, Stacia M DeSantis, Ashraf Yaseen, et al.
Blood
|
April 8, 2025
A phase 1 trial of fully human BCMA CAR-T therapy for relapsed/refractory multiple myeloma with 5-year follow-up
Sherilyn A Tuazon, Andrew J Portuguese, Margot J Pont, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 16, 2001
Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy--results from an international study group
K Fizazi, S Tjulandin, R Salvioni, et al.
Transplantation and Cellular Therapy
|
September 10, 2025
Impact of Gamma-Secretase Inhibition on Outcomes Following BCMA CAR-T Therapy in Multiple Myeloma: A Comparison of Two Phase 1 Trials
Andrew J Portuguese, Sherilyn A Tuazon, Margot J Pont, et al.
Gastroenterology
|
October 31, 2000
Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group
W Fischbach, B Dragosics, M E Kolve-Goebeler, et al.
Page
of 14